Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
Publication:903293
DOI10.1214/10-STS333zbMath1328.62598arXiv1011.6479OpenAlexW2952060368MaRDI QIDQ903293
Mourad Tighiouart, André Rogatko
Publication date: 5 January 2016
Published in: Statistical Science (Search for Journal in Brave)
Full work available at URL: https://arxiv.org/abs/1011.6479
cancer phase I trialsdose-limiting toxicityescalation with overdose controloptimal Bayesian feasibletolerated dose
Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian problems; characterization of Bayes procedures (62C10) Medical applications (general) (92C50)
Related Items (9)
Uses Software
Cites Work
- Unnamed Item
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Unifying CRM and EWOC designs for phase I cancer clinical trials
- Optimal Bayesian-feasible dose escalation for cancer phase I trials
- Dose finding in drug development.
- Coherence principles in dose-finding studies
- TWO-SAMPLE CONTINUAL REASSESSMENT METHOD
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials
This page was built for publication: Dose finding with escalation with overdose control (EWOC) in cancer clinical trials